All In Biotech

Investigational drug · Phase 3

Cagrilintide

Not approved by FDA. In 20 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Type 2 Diabetes.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

20

8 still active

All registered trials

45

Any phase or sponsor naming "Cagrilintide"

First trial start

2022

Nov 1, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cagrilintide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Obesity
  • Overweight
  • Type 2 Diabetes
  • Type 2 Diabetes Mellitus
  • Obesity or Overweight
  • Hypertension
  • Cardiovascular Disease
  • Alcohol-related Liver Disease
  • Chronic Kidney Disease
  • Diabetes Mellitus, Type 2

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Cagrilintide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 107 on PubMed

Also in development for Obesity

  • BerobenatidePF-08653944, MET097Phase 319 trials

    Pfizer · Obesity, Overweight and/or Obesity, Overweight

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.